These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. Boruchoff SE; Sturgill MG; Grasing KW; Seibold JR; McCrea J; Winchell GA; Kusma SE; Deutsch PJ Clin Pharmacol Ther; 2000 Apr; 67(4):351-9. PubMed ID: 10801243 [TBL] [Abstract][Full Text] [Related]
4. The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Cato A; Cavanaugh J; Shi H; Hsu A; Leonard J; Granneman R Clin Pharmacol Ther; 1998 Apr; 63(4):414-21. PubMed ID: 9585795 [TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA; Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762 [TBL] [Abstract][Full Text] [Related]
6. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers. Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838 [TBL] [Abstract][Full Text] [Related]
7. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Krishna G; Parsons A; Kantesaria B; Mant T Curr Med Res Opin; 2007 Mar; 23(3):545-52. PubMed ID: 17355736 [TBL] [Abstract][Full Text] [Related]
10. Bioavailability of two oral suspension and two oral tablet formulations of acyclovir 400 mg: two single-dose, open-label, randomized, two-period crossover comparisons in healthy Mexican adult subjects. Palma-Aguirre JA; Absalón-Reyes JA; Novoa-Heckel G; de Lago A; Oliva I; Rodríguez Z; González-de la Parra M; Burke-Fraga V; Namur S Clin Ther; 2007 Jun; 29(6):1146-52. PubMed ID: 17692728 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers. Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765 [TBL] [Abstract][Full Text] [Related]
13. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers. Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579 [TBL] [Abstract][Full Text] [Related]
14. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Vaidyanathan S; Maboudian M; Warren V; Yeh CM; Dieterich HA; Howard D; Dole WP Curr Med Res Opin; 2008 Aug; 24(8):2313-26. PubMed ID: 18786303 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Smith WB; Dowell JA; Pratt RD Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688 [TBL] [Abstract][Full Text] [Related]
16. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760 [TBL] [Abstract][Full Text] [Related]
17. Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation. Brainard DM; Kassahun K; Wenning LA; Petry AS; Liu C; Lunceford J; Hariparsad N; Eisenhandler R; Norcross A; DeNoia EP; Stone JA; Wagner JA; Iwamoto M J Clin Pharmacol; 2011 Jun; 51(6):943-50. PubMed ID: 20852006 [TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics and safety profile of oral ganciclovir combined with zalcitabine or stavudine in asymptomatic HIV- and CMV-seropositive patients. Jung D; AbdelHameed MH; Teitelbaum P; Dorr A; Griffy K J Clin Pharmacol; 1999 May; 39(5):505-12. PubMed ID: 10234599 [TBL] [Abstract][Full Text] [Related]